Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02433977 · ClinicalTrials.gov registry record · Phase 2

The Effects of NOx and Conjugated Linoleic Acid on Asthmatics

A Phase 2 study of Asthma, sponsored by Gladwin, Mark, MD.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT02433977 is a Phase 2 study of Asthma that has completed, run by Gladwin, Mark, MD. The registered enrollment target is 6 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02433977, a Phase 2 study of Asthma, has completed, sponsored by Gladwin, Mark, MD.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This study will examine the hypothesis that in obese asthmatics; treatment with NOx + CLA is well tolerated, safe and will increase eNO while reducing airway oxidative stress. Allied with this, the investigators will define whether supplementing with this bioactive mediator modifies the airway microbiome, and reduces airway inflammation.

Conditions Studied

Interventions

  • DRUG Sodium Nitrate
  • DIETARY_SUPPLEMENT Conjugated Linolenic Acid
  • DRUG Sodium Nitrite

Study Locations (1)

Pennsylvania

  • The University of Pittsburgh Asthma Institute at UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2015-09
Est. Completion 2019-11
Phase Phase 2

Sponsor

Gladwin, Mark, MD

11 total trials

What the Registry Record Tells You About NCT02433977

The ClinicalTrials.gov registry entry for NCT02433977 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (100% lower). The listed sponsor is Gladwin, Mark, MD, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Sodium Nitrate is the first listed.

NCT02433977 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02433977 about?

NCT02433977 is a clinical study titled "The Effects of NOx and Conjugated Linoleic Acid on Asthmatics". This study will examine the hypothesis that in obese asthmatics; treatment with NOx + CLA is well tolerated, safe and will increase eNO while reducing airway oxidative stress. Allied with this, the investigators will define whether supplementing with this bioactive mediator modifies the airway micro...

What is the current status of trial NCT02433977?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-09. Estimated completion is 2019-11.

What conditions does trial NCT02433977 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT02433977?

The interventions under investigation include: Sodium Nitrate (DRUG), Conjugated Linolenic Acid (DIETARY_SUPPLEMENT), Sodium Nitrite (DRUG).

Who is sponsoring clinical trial NCT02433977?

This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02433977 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.